Jeffrey M. Leiden
2017 - Vertex Pharmaceuticals
In 2017, Jeffrey M. Leiden earned a total compensation of $17.2M as Chairman, President & CEO at Vertex Pharmaceuticals, a 1% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $3,463,200 |
|---|---|
| Option Awards | $3,700,877 |
| Salary | $1,300,000 |
| Stock Awards | $8,750,114 |
| Other | $13,110 |
| Total | $17,227,301 |
Leiden received $8.8M in stock awards, accounting for 51% of the total pay in 2017.
Leiden also received $3.5M in non-equity incentive plan, $3.7M in option awards, $1.3M in salary and $13.1K in other compensation.
Rankings
In 2017, Jeffrey M. Leiden's compensation ranked 209th out of 14,666 executives tracked by ExecPay. In other words, Leiden earned more than 98.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 209 out of 14,666 | 99th |
Division Manufacturing | 56 out of 5,770 | 99th |
Major group Chemicals And Allied Products | 16 out of 2,074 | 99th |
Industry group Drugs | 12 out of 1,730 | 99th |
Industry Pharmaceutical Preparations | 11 out of 1,329 | 99th |
Source: SEC filing on April 17, 2018.
Leiden's colleagues
We found six more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2017.
2017
Michael Parini
Vertex Pharmaceuticals
EVP & Chief Legal and Administrative Officer
2017
Ian Smith
Vertex Pharmaceuticals
Chief Operating Officer
2017
David Altshuler
Vertex Pharmaceuticals
Chief Scientific Officer
2017
Amit Sachdev
Vertex Pharmaceuticals
EVP & Chief Regulatory Officer
2017
Stuart Arbuckle
Vertex Pharmaceuticals
EVP & Chief Commercial Officer
2017
Thomas Graney
Vertex Pharmaceuticals